- Home
- ILLU vs PROK Comparison
ILLU vs PROK Comparison
Compare ILLU & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ILLU | PROK |
|---|---|---|
| Founded | 2025 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 312.0M | 359.4M |
| IPO Year | 2025 | 2021 |
Fundamental Metrics
Financial Performance| Metric | ILLU | PROK |
|---|---|---|
| Price | $9.98 | $1.15 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $6.50 |
| AVG Volume (30 Days) | 133.7K | ★ 1.4M |
| Earning Date | N/A | 11-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $893,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 1075.00 |
| 52 Week Low | $9.90 | $0.87 |
| 52 Week High | $10.01 | $2.95 |
Technical Indicators
Market Signals| Indicator | ILLU | PROK |
|---|---|---|
| Relative Strength Index (RSI) | 54.85 | 36.27 |
| Support Level | $9.97 | N/A |
| Resistance Level | $10.00 | $2.01 |
| Average True Range (ATR) | 0.00 | 0.14 |
| MACD | -0.00 | -0.03 |
| Stochastic Oscillator | 28.77 | 37.91 |
Price Performance
Historical ComparisonAbout ILLU Illumination Acquisition Corp I Class A Ordinary Shares
Illumination Acquisition Corp I is a blank check company formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company pioneering the development of a first-in-class, autologous cell therapy that is intended to preserve kidney function in patients with advance chronic kidney disease (CKD) and diabetes. Its product candidate, REACT (Renal Autologous Cell Therapy), is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.